quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 8, 2026

The 10 ZIP Codes Where $1M Is Chump Change

View original at finance.yahoo.com
The 10 ZIP Codes Where $1M Is Chump Change Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Home price growth in 2026 will stick close to overall consumer price inflation, roughly 2% to 3%

    80% confidence

  • The biggest trend that we're most excited to see is an improvement in affordability. That's going to be good news for buyers and a contributor to the fact that home sales will finally start to go up

    80% confidence

  • Wage growth is expected to rise slightly faster than consumer price inflation and home prices, creating a situation where income is rising faster

    80% confidence

  • We are seeing a little better condition for more home sales with more inventory and the lock in effect steadily disappearing because life changing events are making more people list their property to move on to their next home

    80% confidence

  • Even with progress in affordability, middle income buyers can afford to buy just 21% of the homes currently available for sale. Before the pandemic, they could afford about 50%

    80% confidence

  • Home sales expected to increase by about 14% nationwide in 2026

    80% confidence

Data points we hold from this source

Elf Labs · licensing countries30 countries

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
The 10 ZIP Codes Where $1M Is Chump Change — Source | Via News | pt.VIA.NEWS